Assessment of Type II Diabetes Medication and Its drug-related Adverse effects.

Background: Assessing a patient with Type 2 Diabetes (T2DM) involves a comprehensive evaluation of their medical history, current symptoms, physical examination, and laboratory tests. Here's a structured approach to assessing a patient with T2DM. Evaluate the patient's current diabetes management plan, including diet, exercise, medication adherence, self-monitoring of blood glucose, and insulin administration if applicable. Assess barriers to effective diabetes management, such as socioeconomic factors, access to healthcare, health literacy, and psychosocial support. Collaborate with the patient to set individualized goals for glycemic control, blood pressure, lipid levels, weight management, and prevention of diabetes-related complications. Materials and methods: A six-month longitudinal study was conducted at a tertiary care facility. Those with type 2 diabetes who were receiving insulin and oral hypoglycemics were included in the trial. Laboratory investigations and a sociodemographic profile were gathered using a pretested, structured questionnaire. EPI Info, Open EPI, and SPSS 22 version software were used for the statistical analysis. The statistical tests were the Students t-test and the Chi-square test. Result: There were ninety-nine diabetic individuals in the oral group. Oral hypoglycemics were 46.8±7.6 years old on average. Our research indicates that type II diabetes can be treated with both monotherapy and combination medications. According to the results of this study, the majority of doctors first prescribed monotherapy (25%) consisting of Metformin, Glipizide, Glimepiride, and Gliclazide to control hyperglycemia. Then came triple treatment (40%) including Metformin + Glimepiride + Pioglitazone and dual therapy (35%) comprising FDC of Metformin + Pioglitazone, Metformin + Glipizide, Metformin + Glimepiride, Metformin + Saxagliptin, and Metformin + Voglibose. Conclusion: The most often given medications in our research were biguanide, metformin, and sulfonylureas, such as glimepiride, glibenclamide, glipizide, and gliclazide. [ABSTRACT FROM AUTHOR]